It has been reported that durable response to venetoclax is associated with high expression of Bcl-2 and/or Bim in acute myeloid leukemia (AML) [31], and Bcl-2 family (phospho)protein levels have been shown to associate with sensitivity to venetoclax in CLL, multiple myeloma (MM), and mantle cell lymphoma (MCL) [32–34]. The gene discussed is BCL2L11; the disease is plasma cell myeloma.